Search by Journal

The Japanese Society of Psychiatric Pharmacy

Volume , Issue suppl / 2023
English Article   Japanese Article
  • Please note that metadata of J-type articlesare generated by machine-translation and the original texts are written in Japanese.
Japanese Article The seventh Japan mind Pharmaceutical Society general meeting, psychiatry medical therapy - greetings to join academic meeting - medicine and a heart and society together
梅田賢太
The Japanese Society of Psychiatric Pharmacy (suppl): 3-3, 2023.
Japanese Article Psychiatry, the pharmacy which is connected
梅田賢太
The Japanese Society of Psychiatric Pharmacy (suppl): 32-32, 2023.
Japanese Article The front line of the hierarchy longitudinal study on the heels of a biological base of the stress
古屋敷智之
The Japanese Society of Psychiatric Pharmacy (suppl): 33-33, 2023.
Japanese Article Clinical practice and the condition of a patient of antiNMDA receptor encephalitis
高木学
The Japanese Society of Psychiatric Pharmacy (suppl): 34-34, 2023.
Japanese Article Expectation to psychiatry pharmacist enlarging the place of the achievement
筒井由佳
The Japanese Society of Psychiatric Pharmacy (suppl): 35-35, 2023.
Japanese Article Management of the polypharmacy in the psychiatry medical therapy
坂本靖之
The Japanese Society of Psychiatric Pharmacy (suppl): 36-36, 2023.
Japanese Article S1-1. Polypharmacy in the psychiatry medical therapy: Summary
野田幸裕
The Japanese Society of Psychiatric Pharmacy (suppl): 37-37, 2023.
Japanese Article S1-2. A sleeping drug and polypharmacy
井上真一郎
The Japanese Society of Psychiatric Pharmacy (suppl): 38-38, 2023.
Japanese Article S1-3. We arrange polypharmacy in depression treatment
肥田裕丈, 山田清文
The Japanese Society of Psychiatric Pharmacy (suppl): 39-39, 2023.
Japanese Article S1-4. Schizophrenia and polypharmacy
亀井浩行
The Japanese Society of Psychiatric Pharmacy (suppl): 40-40, 2023.
Japanese Article It is ... in attentive ears with introduction to DI utilization - professor in Bar Prova
別所千枝
The Japanese Society of Psychiatric Pharmacy (suppl): 41-41, 2023.
Japanese Article S2-1. The clinical on-site practical article search that becomes fun to be able to make use of to be able to look for
桑原秀徳
The Japanese Society of Psychiatric Pharmacy (suppl): 42-42, 2023.
Japanese Article S2-2. It is a way of thinking package insert, how to read RMP
冨田隆志
The Japanese Society of Psychiatric Pharmacy (suppl): 43-43, 2023.
Japanese Article S2-3. Exploring of the information sharing method necessary for giving capacity for organization
葛葉里奈
The Japanese Society of Psychiatric Pharmacy (suppl): 44-44, 2023.
Japanese Article It is regional alliances ... utilizing future ... tracing report of the health insurance pharmacy for the inclusion in this
栗原正亮
The Japanese Society of Psychiatric Pharmacy (suppl): 45-45, 2023.
Japanese Article S3-1. Cooperation with the specialist in prescription utilizing the tracing report
福田和博
The Japanese Society of Psychiatric Pharmacy (suppl): 46-46, 2023.
Japanese Article S3-2. About a tracing report, the medicine medicine cooperation utilizing the discharge drug reporting book and the multi-type of job cooperation in the treatment at home
栗原正亮
The Japanese Society of Psychiatric Pharmacy (suppl): 47-47, 2023.
Japanese Article S3-3. Local shift support task of the hospital pharmacist
山田雅彦
The Japanese Society of Psychiatric Pharmacy (suppl): 48-48, 2023.
Japanese Article S3-4. About a tracing report of this meeting community medical care cooperation promotion Committee making
和田智仁1), 有山智博2), 大向香織3), 栗原正亮4), 鈴木弘道5), 中田裕介6), 竹内尚子7)
The Japanese Society of Psychiatric Pharmacy (suppl): 49-49, 2023.
Japanese Article S3-5. Possibility of the multi-type of job cooperation using the document including a tracing report
中田裕介
The Japanese Society of Psychiatric Pharmacy (suppl): 50-50, 2023.
Japanese Article The application of the IT technique in the psychiatric practice and the future prospects
江角悟
The Japanese Society of Psychiatric Pharmacy (suppl): 51-51, 2023.
Japanese Article S4-1. Purpose explanation
北村佳久1), 江角悟2)
The Japanese Society of Psychiatric Pharmacy (suppl): 52-52, 2023.
Japanese Article S4-2. An education effect and problem in the online medication counseling training in the pharmacy school
河野奨
The Japanese Society of Psychiatric Pharmacy (suppl): 53-53, 2023.
Japanese Article S4-3. Practice of the online consultation system for the improvement in quality of the psychiatry medical therapy
江角悟1), 座間味義人2)
The Japanese Society of Psychiatric Pharmacy (suppl): 54-54, 2023.
Japanese Article S4-4. It is development of powdered medicine inspection support system "kona mil PLUS" one package using the spectrophotometric analysis
森山圭
The Japanese Society of Psychiatric Pharmacy (suppl): 55-55, 2023.
Japanese Article S4-5. A fact and the prospects of the ICT utilization in the drugstore duties to patients during psychiatry going to hospital
肥後昇平
The Japanese Society of Psychiatric Pharmacy (suppl): 56-56, 2023.
Japanese Article Aim; "mental Pharmaceutical Society authorization pharmacist!"
木藤弘子
The Japanese Society of Psychiatric Pharmacy (suppl): 57-57, 2023.
Japanese Article S5-1. The thing which an evaluation and authorization of the specialty of the pharmacist in psychiatry, the pharmacy domain mean
梅田賢太
The Japanese Society of Psychiatric Pharmacy (suppl): 58-58, 2023.
Japanese Article S5-2. How do you acquire "mental Pharmaceutical Society authorization pharmacist?"
椎崇
The Japanese Society of Psychiatric Pharmacy (suppl): 59-59, 2023.
Japanese Article S5-3. It is the Japanese alphabet and a point of the psychiatry case report the measures that an authorized pharmacist passes
出川えりか
The Japanese Society of Psychiatric Pharmacy (suppl): 60-60, 2023.
Japanese Article S5-4. About the point of "the authorized study"
永井努
The Japanese Society of Psychiatric Pharmacy (suppl): 61-61, 2023.
Japanese Article S5-5. About the pharmacist acquisition specialized in Japanese Society of Hospital Pharmacists psychiatry medical therapy authorization pharmacist, psychiatry
木藤弘子
The Japanese Society of Psychiatric Pharmacy (suppl): 62-62, 2023.
Japanese Article PCP Study Group Project Let's think about better drug treatment - "Case Study" Depression -
吉尾隆1), 柴田木綿2), 吉見陽3), 志田雅彦4), 高橋結花5), 中川将人6), 宇野準二7), 宮原佳希8)
The Japanese Society of Psychiatric Pharmacy (suppl): 63-63, 2023.
Japanese Article The most important technique for "listening" to a patient is...↓↓ The basics of interpersonal communication learned from motivational interviewing
細川智成1), 宮浦淳一2), 北川航平3), 細木加寿子4), 高橋結花5), 高橋満里6)
The Japanese Society of Psychiatric Pharmacy (suppl): 63-63, 2023.
Japanese Article "HAM - D (Hamilton depression scale) dojo studio"
谷藤弘淳1), 堀輝2), 天正雅美3)
The Japanese Society of Psychiatric Pharmacy (suppl): 64-64, 2023.
Japanese Article Efforts for the proper use of the drug in schizophrenia
榊原崇
The Japanese Society of Psychiatric Pharmacy (suppl): 65-65, 2023.
Japanese Article Study about the effect to give to activity - sleep of patients with mental disorder by the benzodiazepine system medicine gradual decrease using the Actigraph
植草秀介
The Japanese Society of Psychiatric Pharmacy (suppl): 66-66, 2023.
Japanese Article The therapeutic role of LONASEN Tapes in acute schizophrenia : results of a systematic review
岸太郎
The Japanese Society of Psychiatric Pharmacy (suppl): 67-67, 2023.
Japanese Article Tips for continuing to take SDM and Sycrest sublingual tablets in outpatient treatment for schizophrenia - From compliance to concordance -
小野晴久
The Japanese Society of Psychiatric Pharmacy (suppl): 68-68, 2023.
Japanese Article Correspondence and treatment of patients with adult sleep disorder with the nerve development symptom
河邉憲太郎
The Japanese Society of Psychiatric Pharmacy (suppl): 69-69, 2023.
Japanese Article It is ... from "tardive dyskinesia (TD)" summary ... diagnosis to treatment
森康浩
The Japanese Society of Psychiatric Pharmacy (suppl): 70-70, 2023.
Japanese Article Treatment support ... which accepted adults, an each life stage from ... children who "reconsidered positioning of the medical therapy in the ADHD practice"
桝屋二郎
The Japanese Society of Psychiatric Pharmacy (suppl): 71-71, 2023.
Japanese Article Wanting to know it because bipolar disorder medical treatment is provided effectively
堀輝
The Japanese Society of Psychiatric Pharmacy (suppl): 72-72, 2023.
Japanese Article (1). Value (2). of LAI seeing from TRI patients satisfaction investigation About the multi-type of job cooperation LAI introduction program pharmacist-led for LAI treatment promotion
阪岡沙耶香(1), 辛島昌秀(2)
The Japanese Society of Psychiatric Pharmacy (suppl): 73-73, 2023.
Japanese Article O-1-1. Research of the risk factor about the leukopenia derived from Clozapine
佐藤雅也1), 岸田孝一1), 藤田康平2), 三輪高市3)
The Japanese Society of Psychiatric Pharmacy (suppl): 76-76, 2023.
Japanese Article O-1-2. It is ... about the prescription situation of 1 prescription fact-finding (2022) about the medical therapy of patients with schizophrenia - outpatient
加藤剛1,2), 鈴木貴子1), 柴田木綿1), 宇野準二1), 高田憲一1), 梅田賢太1), 天正雅美1), 三輪高市1), 野田幸裕1), 吉尾隆1)
The Japanese Society of Psychiatric Pharmacy (suppl): 76-76, 2023.
Japanese Article O-1-3. The case that evaded fever by the Clozapine resumption at the low dose
松村俊希1), 石川章1), 水村亮介1), 須貝昌平1), 河合史彦2), 真壁秀樹1)
The Japanese Society of Psychiatric Pharmacy (suppl): 77-77, 2023.
Japanese Article O-1-4. It is ... about the prescription tendency of the antiparkinson agent in generalization of the prescription investigation of the prescription fact-finding (2022) about the medical therapy of patients with schizophrenia 2-2022 year and the inpatient
鈴木貴子1,2), 加藤剛1), 柴田木綿1), 宇野準二1), 高田憲一1), 梅田賢太1), 天正雅美1), 三輪高市1), 野田幸裕1), 吉尾隆1)
The Japanese Society of Psychiatric Pharmacy (suppl): 77-77, 2023.
Japanese Article O-1-5. Relation to the use of Clozapine patients in the Saitama Medical University Hospital
須貝昌平1), 新井久稔2), 眞壁秀樹1), 石川章1), 水村亮介1), 松村俊希1)
The Japanese Society of Psychiatric Pharmacy (suppl): 78-78, 2023.
Japanese Article O-1-6. It is ... about a tendency to prescription of the antipsychotics in the ward inpatient for 3 prescription fact-finding (2022) about the medical therapy of patients with schizophrenia - psychiatry first aid acute phase
柴田木綿1,2), 加藤剛2), 鈴木貴子2), 宇野準二2), 梅田賢太2), 高田憲一2), 三輪高市2), 天正雅美2), 野田幸裕2), 吉尾隆2)
The Japanese Society of Psychiatric Pharmacy (suppl): 78-78, 2023.
Japanese Article O-1-7. Patient's share of medical expenses investigation of the medical treatment in patients with schizophrenia
水野博之, 榊原崇
The Japanese Society of Psychiatric Pharmacy (suppl): 79-79, 2023.
Japanese Article O-2-1. The evaluation of the safe signal in consideration of a concomitant drug of sexual dysfunction with antipsychotics: Fur Mako bidiLance study using FDA Adverse Event Reporting System
横井里奈, 波多野正和, 山田成樹
The Japanese Society of Psychiatric Pharmacy (suppl): 79-79, 2023.
Japanese Article O-2-2. Examination - of the causation in antipsychotics and leukopenia - our hospital
辻本千代美1), 久馬透1), 芹生卓1,2), 芝伸太郎1)
The Japanese Society of Psychiatric Pharmacy (suppl): 80-80, 2023.
Japanese Article O-2-3. Report on the results of the reexamination of Paliperidone Palmitate sustained-release injection (Xeplion (R) aqueous suspension for intramuscular injection)
山岸史枝, 若松昭秀, 武部恭子, 木下宏明, 森田夏子, 藤間時子, 山岡俊夫
The Japanese Society of Psychiatric Pharmacy (suppl): 80-80, 2023.
Japanese Article O-2-4. Risk factor analysis of the lamotrigine-induced dermatopathy that assumed medical big data analysis a base
坂東寛1,2), 合田光寛1,2), 新田侑生3), 中馬真幸3), 小川敦1,2), 櫻田巧1,2), 桐野靖1,2), 石澤啓介1,2,4)
The Japanese Society of Psychiatric Pharmacy (suppl): 81-81, 2023.
Japanese Article O-2-5. About the subjective evaluation of patients about the sleeping drug remedy in the health insurance pharmacy
清水侑真1), 浅井航大2), 久田侑歩2), 石黒真由2), 羽實元太3), 竹内亨3), 小林円加4), 石山秀明4), 田中大樹4), 榊原維英4), 橋本歩4), 榎本尚人4), 榊原幹夫4), 半谷眞七子1,2), 亀井浩行1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 81-81, 2023.
Japanese Article O-2-6. A prescription trend by the sleeping drug formula reintroduction and change of the pharmaceutical products purchase costs
水村亮介, 石川章, 朝倉智子, 伊藤護之, 宇都宮暁, 杉本修, 眞壁秀樹
The Japanese Society of Psychiatric Pharmacy (suppl): 82-82, 2023.
Japanese Article O-3-1. Cooperation ... with fact-finding ... family drugstore of the tracing report use and application in the psychiatry domain
加藤剛1,2,3), 三原侑子3), 清水啓子3), 松本有希3), 北田亜美1), 星野雅人1), 宗像彩香1), 澤口真紀1), 田村由美子2), 栗原和博2), 新井公一2), 大熊亜実4), 小見暁子4), 土井信幸4)
The Japanese Society of Psychiatric Pharmacy (suppl): 82-82, 2023.
Japanese Article O-3-2. Trendy analysis about the long-term use of benzodiazepine drugs in this country
百賢二1,2), 嶋崎真耶3), 桐生嘉浩4), 服部はるか1,5), 黒沢雅広1,6)
The Japanese Society of Psychiatric Pharmacy (suppl): 83-83, 2023.
Japanese Article O-3-3. The current situation and problem of the discharge drug reporting by the hospital pharmacist
笠原真理, 鶴谷勝実
The Japanese Society of Psychiatric Pharmacy (suppl): 83-83, 2023.
Japanese Article O-3-4. It is ... mainly on the situation of medication adequacy business - overlap medication to stop by if caused by Tokorozawa-shi pharmacist society and cooperation of Tokorozawa-shi
加藤剛1,2,3), 大塚正征1,3), 斉藤祐次1,3), 田邉浩一郎1,3), 土井信幸3,4)
The Japanese Society of Psychiatric Pharmacy (suppl): 84-84, 2023.
Japanese Article O-4-1. The effect that the medication self-care introduction in the mental hospital gives to patients
公文理紗子, 宇治宏美, 桝井章典, 福田のぞみ, 横江穂奈美, 高畑大平, 下村悠祐, 小河潮美, 末田有土, 山田雅彦
The Japanese Society of Psychiatric Pharmacy (suppl): 84-84, 2023.
Japanese Article O-4-2. Research about the pharmacist intervention to the psychology classroom for patients with schizophrenia
衣笠真澄, 河本理沙, 桑名由樹子, 平本晃子
The Japanese Society of Psychiatric Pharmacy (suppl): 85-85, 2023.
Japanese Article O-4-3. Physician questionary survey about the making of "the drug control summary for psychiatry"
坂本靖之1), 坂井原美希1), 中島綾夏1), 松田将史1), 田頭尚士1), 町野彰彦2), 藤田秀樹1)
The Japanese Society of Psychiatric Pharmacy (suppl): 85-85, 2023.
Japanese Article O-4-4. The effect that dosage form of the oral medicine in the psychiatry gives for the internal use behavior of patients
古屋宏章, 林裕佳子, 安藤睦実, 細川琴実, 米澤夏里, 金森捷太, 八木孝仁, 永井努, 黒沢雅広
The Japanese Society of Psychiatric Pharmacy (suppl): 86-86, 2023.
Japanese Article O-5-1. The effectiveness and safety of the alcohol decrease liquor therapy which we accepted for the duration of treatment in the use of alcoholism or alcohol disorder patients: Systematic review/network meta analysis
小武和正1), 細川智成2), 田中増郎3), 橋本保彦4), 川上恭弘1), 則武有美1)
The Japanese Society of Psychiatric Pharmacy (suppl): 86-86, 2023.
Japanese Article O-5-2. The task which we saw through prescription investigation and the multi-type of job workshop of the alcoholism-related therapeutic drug
佐々木典子1,2), 山本憲彦3), 猪野亜朗4), 兼児敏浩1)
The Japanese Society of Psychiatric Pharmacy (suppl): 87-87, 2023.
Japanese Article O-5-3. A prediction of Modeling & Simulation - blood drug concentration that is feasible by the clinical practice of the psychiatry domain for a case -
森田和弥1), 阿部裕子1), 小場佐仁美1), 宮崎賢三1), 牧坂夏実1), 高橋英範1), 小田浩一2)
The Japanese Society of Psychiatric Pharmacy (suppl): 87-87, 2023.
Japanese Article O-5-4. Effect of the combination drug on delirium risk signal of the benzodiazepine system agonist using the adverse event database
祖川倫太郎, 西村文, 宮本由貴, 島ノ江千里
The Japanese Society of Psychiatric Pharmacy (suppl): 88-88, 2023.
Japanese Article O-5-5. Effect of zinc on anxiety-like symptom with the LPS administration and microglial activation
田中翔哉1), 出石恭久1), 吾郷拓磨1), 植田哲平1), 田坂祐一2), 宮崎育子3), 浅沼幹人3), 北村佳久1)
The Japanese Society of Psychiatric Pharmacy (suppl): 88-88, 2023.
Japanese Article O-5-6. Questionary survey for the pharmaceutical cooperation with the health insurance pharmacy to affect LAI
廣瀬健一郎, 林友美
The Japanese Society of Psychiatric Pharmacy (suppl): 89-89, 2023.
Japanese Article P-1. Cognitive usability test using the psychokinesia function test in the use of alcohol disorder patients
鈴木香帆1), 清水侑真1), 宮浦淳一1,2), 森下夏帆2), 水島久美子2), 内田あおい2), 奥田正英2), 水谷浩明2), 半谷眞七子1), 亀井浩行1)
The Japanese Society of Psychiatric Pharmacy (suppl): 90-90, 2023.
Japanese Article P-2. Prescription fact-finding (Pilot investigation) of the psychotropic drug in the alcoholism inpatient care
宮浦淳一1), 加藤剛2), 五味和彦3), 福山雄卯介4), 細木加寿子5), 細川智成6), 亀井浩行7)
The Japanese Society of Psychiatric Pharmacy (suppl): 90-90, 2023.
Japanese Article P-3. Survey of outpatients with schizophrenia regarding their willingness to receive paliperidone palmitate 3-month preparation (PP3M)
松本早苗, 土田さおり, 山本和幸, 五味和彦
The Japanese Society of Psychiatric Pharmacy (suppl): 91-91, 2023.
Japanese Article P-4. 2 cases that reached side effect reduction, the reduction of the pain of patients by DIEPSS enforcement by the multi-type of job cooperation in the group home in patients receiving sustained-release parenteral injection
成井繁1), 小山貴大1), 山下和美1), 今井亜弥1), 朝倉ゆかり2), 池畑清美2), 加来信也2)
The Japanese Society of Psychiatric Pharmacy (suppl): 91-91, 2023.
Japanese Article P-5. Investigation about the actual situation of the side effect that is hard to be manifested in the medical treatment of patients with bipolar disorder and the cause
森康徳1), 清水侑真1), 竹内一平2), 藤田潔2), 半谷眞七子1), 亀井浩行1)
The Japanese Society of Psychiatric Pharmacy (suppl): 92-92, 2023.
Japanese Article P-6. The effect that attention lack, a hyperactivity disorder (ADHD) therapeutic drug gives to sleep
植草秀介1), 渡部真澄1), 花井雄貴1), 木村伊都紀2), 本郷誠司3), 吉尾隆4,5), 松尾和廣1)
The Japanese Society of Psychiatric Pharmacy (suppl): 92-92, 2023.
Japanese Article P-7. Prescription investigation of the Blonanserin percutaneous absorption type preparation in ambulatory schizophrenia treatment
野島梓, 石原真澄, 櫻井徹, 出川えりか, 齋藤文宏
The Japanese Society of Psychiatric Pharmacy (suppl): 93-93, 2023.
Japanese Article P-8. About the situation of the Clozapine blood level measurement in our hospital
畑尾由佳, 宮浦淳一
The Japanese Society of Psychiatric Pharmacy (suppl): 93-93, 2023.
Japanese Article P-9. Schizophrenia Patient 2 case - during the Clozapine administration that resulted in a neutropenia at intervention - COVID -19 infection to a dose by blood Clozapine densitometry
阿部裕子1), 森田和弥1), 宮崎賢三1), 小場佐仁美1), 牧坂夏実1), 高橋英範1), 林裕子2), 鈴木展子3), 尾田一貴4), 城野博史4)
The Japanese Society of Psychiatric Pharmacy (suppl): 94-94, 2023.
Japanese Article P-10. Investigation (the first report) about the development of thromboembolism situation in the antipsychotics internal use patients during our hospital neuropsychiatry ward hospitalization
渡部和幸1), 田中義人2), 舟越亮寛1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 94-94, 2023.
Japanese Article P-11. The constipation aggravation of patients with schizophrenia and relations (preliminary study) of the prescribed medicine
灘谷聡昭, 稲熊徳也, 長尾知子
The Japanese Society of Psychiatric Pharmacy (suppl): 95-95, 2023.
Japanese Article P-12. About use experience of valbenazine in the Okehazama Hospital Fujita heart care center
竹内一平1,2), 半谷眞七子2), 藤田潔1), 亀井浩行2)
The Japanese Society of Psychiatric Pharmacy (suppl): 95-95, 2023.
Japanese Article P-13. Satisfaction investigation about the sleep situation and the sleeping drug of patients except the psychiatry in the health insurance pharmacy
久田侑歩1), 清水侑真1), 榎本尚人2), 榊原幹夫2), 田中大樹2), 榊原維英2), 橋本歩2), 半谷眞七子1), 亀井浩行1)
The Japanese Society of Psychiatric Pharmacy (suppl): 96-96, 2023.
Japanese Article P-14. Retrospective cohort study ... which intended for relative - elective surgery patients with the delirium after the hydroxyzine hydrochloride injection and the operation
上條貢, 瀬川亮, 宮澤正幸, 喜古康博
The Japanese Society of Psychiatric Pharmacy (suppl): 96-96, 2023.
Japanese Article P-15. Effect on sleep state with addition, the change administration of orexin receptor blocker (ORA) in patients during benzodiazepine receptor (BZ) agonist remedy (anteroposterior comparative study)
前原雅樹, 杉山正康
The Japanese Society of Psychiatric Pharmacy (suppl): 97-97, 2023.
Japanese Article P-16. Efforts and problem of the discharge reporting book in the psychiatry
鈴木昭雄
The Japanese Society of Psychiatric Pharmacy (suppl): 97-97, 2023.
Japanese Article P-17. Of the at-home visit by the pharmacist of the ethical pharmacy in the psychiatry domain, actually
上條千恵子
The Japanese Society of Psychiatric Pharmacy (suppl): 98-98, 2023.
Japanese Article P-18. Investigation of the actual situation of the polypharmacy in our hospital supermarket emergency ward inpatient and pharmaceutical intervention contents
辛島昌秀, 植木ひとみ, 小沼和寛, 照沼貴弘
The Japanese Society of Psychiatric Pharmacy (suppl): 98-98, 2023.
Japanese Article P-19. 5 intracerebral - HT2A receptor function is enhanced by systemic inflammation with the LPS administration
植田哲平1), 出石恭久1), 吾郷拓磨1), 田中翔哉1), 宮崎育子2), 浅沼幹人2), 北村佳久1)
The Japanese Society of Psychiatric Pharmacy (suppl): 99-99, 2023.
Japanese Article P-20. Enforcement of the psychiatry training in the pharmacy business training
近藤浩樹1), 崔友子1), 上條千恵子1), 倉岡徹1), ジョーンズ千絵1), 羽佐田祥浩2), 和田智仁2), 三輪歌織2)
The Japanese Society of Psychiatric Pharmacy (suppl): 99-99, 2023.
Japanese Article P-21. Effect on in paired performance using the psychokinesia function test by the antihistamine remedy in patients with skin disease
大橋幸輝1), 山崎紗矢1), 羽實元太2), 辛島里帆子1), 竹内亨2), 半谷眞七子1), 亀井浩行1)
The Japanese Society of Psychiatric Pharmacy (suppl): 100-100, 2023.
Japanese Article P-22. The current situation investigation of the medication self-care in the Hiroshima mental hospital
山田雅彦1), 岩本竜昇2), 阪岡倫行3), 佐藤佳子4), 石井由美子5), 新宅将史6)
The Japanese Society of Psychiatric Pharmacy (suppl): 100-100, 2023.
Japanese Article P-23. Example that tried the medicine that it decreased by it of the symptomatic treatment medicine and side effect reduction for patients admitted to another hospital for a long term in an own institution
中島理恵1), 西尾公志1), 松尾待池2), 片山陽介1), 古海和博1)
The Japanese Society of Psychiatric Pharmacy (suppl): 101-101, 2023.
Japanese Article P-24. Evaluation by a physician, the nurse of the ward drug duties in the seaside forest hospital which is a mental hospital
細木加寿子1), 武田真苗1), 中西晴幸1), 加藤剛2)
The Japanese Society of Psychiatric Pharmacy (suppl): 101-101, 2023.
▲